Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in <i>MET</i> -Amplified Esophagogastric CancerEunice L. Kwak, Ryan B. Corcoran, Lawrence S. Blaszkowsky et al.|Cancer Discovery|2015Cited by 168
Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in <i>BRAF</i> V600E Colorectal CancerMehlika Hazar-Rethinam, Ryan B. Corcoran, Marianna Kleyman et al.|Cancer Discovery|2018Cited by 73
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid TumorsRyan B. Corcoran, Geoffrey I. Shapiro, T. Khanh et al.|Clinical Cancer Research|2024Cited by 39
Abstract 5584: Experimental ‘loss-of function’ annotation of STK11 mutations with prognostic and therapeutic implications (TNG260mutationfinder.com)Leanne G. Ahronian, Teng Teng, Preksha Shahagadkar et al.|Cancer Research|2024Cited by 0